Difference between revisions of "Elotuzumab (Empliciti)"
m |
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
||
| Line 5: | Line 5: | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert.<ref name=insert></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
Revision as of 15:29, 3 December 2017
General information
Class/mechanism: Humanized IgG1 monoclonal antibody which targets SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7). SLAMF7 is a protein which is expressed on myeloma cells, Natural Killer cells, plasma cells, and expressed at lower levels on certain immune cell subsets of differentiated cells. Elotuzumab facilitates antibody-dependent cellular cytotoxicity (ADCC) between myeloma cells and Natural Killer cells. The antigen target of elotuzumab may also be known as CS1 (CD2 subset 1, CRACC, SLAMF7).[1][2][3][4]
[5]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 5/19/2014: Granted FDA Breakthrough Therapy designation "for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies."
- 11/30/2015: FDA approved to be used "in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies."
Also known as
- Code names: BMS-901608, HuLuc63, PDL063, PDL-063
- Generic name: anti-CS1 monoclonal antibody HuLuc63
- Brand name: Empliciti